Germany stakes its claim over Curevac
The German government will not get exclusive access to Curevac’s Covid-19 vaccine as part of its 23% stake purchase, the company insists.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Astrazeneca moves to upstage Moderna in Covid-19 vaccines
The UK big pharma group unveils funding and a clinical programme that could overshadow the efforts of its biotech rival.
Moderna reminds the markets of biotech’s dual purpose
On the back of coronavirus mania, Moderna, a $30bn company heavily funded by the US government, taps investors for $1.3bn.
Lonza to do the heavy lifting for Moderna’s Covid-19 vaccine
Moderna becomes the latest coronavirus vaccine player to act on the need for a major manufacturing push.
AACR 2020 preview – no Tigit, but plenty of novel mechanisms
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
Big Pharma throws out old models in the race to a Covid-19 vaccine
From research collaborations to changes to drug development, pharma will have to find new ways of working to discover Covid-19 treatments.
What to look for in upcoming Covid-19 trial readouts
Industry-sponsored clinical studies against the new coronavirus have proliferated, as have their designs and efficacy measures.
The long path to an effective coronavirus vaccine
What is biopharma doing to develop vaccines against Covid-19, and what are the properties of each approach? Vantage takes a look.
